Details for Patent: 5,856,529
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 5,856,529 protect, and when does it expire?
Patent 5,856,529 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has thirty-one patent family members in twenty-four countries.
Summary for Patent: 5,856,529
Title: | Benzofuran and dihydrobenzofuran melatonergic agents |
Abstract: | Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents. |
Inventor(s): | Catt; John D. (Southington, CT), Johnson; Graham (Madison, CT), Keavy; Daniel J. (Killingworth, CT), Mattson; Ronald J. (Meriden, CT), Parker; Michael F. (Middletown, CT), Takaki; Katherine S. (Middletown, CT), Yevich; Joseph P. (Southington, CT) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 08/987,478 |
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Drugs Protected by US Patent 5,856,529
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON | See Plans and Pricing | ||
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | See Plans and Pricing | ||
Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 5,856,529
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 010346 | See Plans and Pricing | |||
Austria | 281833 | See Plans and Pricing | |||
Australia | 5598598 | See Plans and Pricing | |||
Australia | 719994 | See Plans and Pricing | |||
Brazil | 9713690 | See Plans and Pricing | |||
Canada | 2274183 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |